Vectura Plc: Evaluating the Effect of Product Success / Failure on Share Price

Torux Biotech together with Biostrategy Analytics have published an Analyst Report relating to Vectura Plc, a listed (LON:VEC) pharmaceutical company focused on Chronic Obstructive Pulmonary Disease (COPD) and Asthma indications. The report can be found in the link below:

Vectura Report

The aim of this report is to evaluate the effect of potential success / failure of clinical trial products on the share price of Vectura Plc using variations of risk Adjusted Net Present Value (rNPV) methodologies. In addition, a brief revenue & market analysis of the market segment in which Vectura is active, has been performed.


Dimitris uses its unique blend of studies in Management and Biotech combined with his quick witted entrepreneurial spirit to provide deep insights into strategic and financial aspects of the Biotech industry.

Leave a Reply

Your email address will not be published. Required fields are marked *